Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 8/14/24 → 8/14/27 |
Funding
- Kura Oncology Incorporated: $392,153.00
24-LEUK-25-KO-PMC (KO-MEN-007): Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination with Ziftomenib (KO-539) or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients wit
- Qasrawi, Ayman (PI)